Biotech firm Carmine Therapeutics inks US$900m deal with Takeda Pharmaceutical
The tie-up aims to discover, develop and commercialise two rare-disease drugs
Add BT as a preferred sourceSingapore
CARMINE Therapeutics, a biotech firm developing non-viral gene therapies for rare diseases, on Wednesday said it has signed a US$900 million research agreement with Takeda Pharmaceutical Company to discover, develop and commercialise two rare-disease drugs.
The company will receive an upfront payment to support its research, but the remaining amount will be doled out when the firm hits milestones such as pre-clinical studies, clinical trials and during commercialisation. Tiered royalties are also included in the deal.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
